News
Freshfields advises CVC Capital Partners IX on $925m acquisition of Therakos from Mallinckrodt
Global law firm Freshfields Bruckhaus Deringer (‘Freshfields’) is advising CVC Capital Partners (‘CVC’), one of the world’s leading investment firms, on its carve-out acquisition of the Therakos business from global specialty pharma company Mallinckrodt.
Therakos is a fully integrated extracorporeal photopheresis (ECP) delivery system for autologous immunomodulatory therapy. With approvals for use in the U.S., Canada, Europe, Japan, Australia and Latin America, it is the platform-of-choice among healthcare providers and patients to treat a range of immune-related diseases. CVC Capital Partners IX will acquire Therakos for an enterprise value of $925m, subject to customary adjustments.
The transaction is expected to close in the fourth quarter of 2024.
The Freshfields team advising longstanding client CVC is led out of New York by Global Co-Head of Private Capital Neal J. Reenan, Head of US Private Capital Ian N. Bushner, and with support from Global Co-Head of Private Capital Charles Hayes in London.
The Leveraged Finance team is led by Head of US Leveraged Finance Allison Liff. Specialist Life Sciences advice is being provided by Head of US Life Sciences Transactions Adam Golden.
The team includes partners Mena Kaplan (New York), Joe Soltis (New York), Jill Gatehouse (London), Emily Szasz (London), Lori Goodman (New York), and Bruce McCulloch (DC), counsel Michal Netanyahu (New York), senior associates Edmund Haxby (New York), Daniel Spencer (DC), Madeleine Tavcar (New York) and Kelsey Avery (New York), and associates Connor Smith (New York), Allison Caramico (New York), Laura Zhu (New York), Oscar Berry (London) and Charlotte Bourne (London).
Details of the transaction can be found here.
